Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 1277

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 7A
Chunk 1277
---
 Level 3 measurement because they are supported by little or no market activity and reflect
the Company’s own assumptions in measuring fair value. The assumptions used in the impairment analysis are inherently subject to
uncertainty and, therefore, changes in these assumptions could have a significant impact on the concluded fair value.

See Note 4 related to other intangible assets acquired
during the year ended December 31, 2023.

    F-28

Amortization expense for intangible assets for the
years ended December 31, 2024 and 2023 were as follows:

 SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS

    2024  
    2023 

    For the Years Ended December 31, 

    2024  
    2023 
  
    Patents 
    $56,000  
    $84,000 
  
    Licenses 
     35,000  
     7,000 
  
    Acquired NDAs 
     11,669,000  
     9,937,000 
  
    Customer relationships 
     22,000  
     54,000 
  
    Trade name 
     1,000  
     - 
  
    Amortization
    expense of intangible assets 
    $11,783,000  
    $10,082,000 

Estimated future amortization expense for the Company’s
intangible assets at December 31, 2024 is as follows:

 SCHEDULE
OF ESTIMATED FUTURE AMORTIZATION EXPENSE

    Years ending December 31, 

    2025 
    $16,903,000 
  
    2026 
     16,903,000 
  
    2027 
     16,612,000 
  
    2028 
     16,205,000 
  
    2029 
     16,095,000 
  
    Thereafter 
     102,001,000 
  
    Intangible
    assets 
    $184,719,000 

In connection with an asset purchase agreement between
Novartis and the Company, the Company recognized a $37,000,000 milestone payment during 2024 following the release of the first commercially
available batch of TRIESENCE. The milestone payment was recognized as an increase in the amount of intangible assets for Acquired NDAs.

There